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Semiconductor quantum dots (QDs) have recently been used to deliver and monitor biomolecules, such as drugs and proteins.
However, QDs alone have a low eﬃciency of transport across the plasma membrane. In order to increase the eﬃciency, we
used synthetic nona-arginine (SR9), a cell-penetrating peptide, to facilitate uptake. We found that SR9 increased the cellular
uptake of QDs in a noncovalent binding manner between QDs and SR9. Further, we investigated mechanisms of QD/SR9
cellular internalization. Low temperature and metabolic inhibitors markedly inhibited the uptake of QD/SR9, indicating that
internalization is an energy-dependent process. Results from both the pathway inhibitors and the RNA interference (RNAi)
technique suggest that cellular uptake of QD/SR9 is predominantly a lipid raft-dependent process mediated by macropinocytosis.
However, involvement of clathrin and caveolin-1 proteins in transducing QD/SR9 across the membrane cannot be completely
ruled out.
1.Introduction
Fluorescent semiconductor quantum dots (QDs) have been
used to deliver and monitor biomolecules into cells in the
past few years [1–3]. Advantages of QDs over traditional
dyes and proteins (e.g., green and red ﬂuorescent proteins)
include their unique physical and chemical properties,
namely,photostability,highquantumyield,narrowemission
peak, exceptional resistance to degradation, broad size-
dependent photoluminescence, and multiplexing potential
[4]. Although QDs can be engulfed by living cells, the use
of cell-penetrating peptides can increase uptake eﬃciency
[5].
The study of the uptake mechanism of QDs is just
beginning. Using speciﬁc inhibitors, Ruan et al. identiﬁed
macropinocytosis, actin ﬁlaments, and microtubules as
required for internalization and intracellular transport
of streptavidin-coated QD/Tat-biotin in HeLa cells [6].
Zhang and Monteiro-Riviere demonstrated that carboxylic
QDs were internalized by lipid raft-dependent endocytosis
in human epidermal keratinocytes, and these pathways
were primarily regulated by the G-protein-coupled recep-
tor associated pathway and low-density lipoprotein recep-
tor/scavenger receptor [7].
Cell-penetrating peptides (CPPs), also known as protein
transduction domains (PTDs) or membrane transduction
peptides (MTPs), have been used to transduce biologically
active proteins, siRNA, and drugs across plasma membranes
[8, 9]. The advantages of CPPs include ease of prepara-
tion, lack of toxicity to the cell, and high eﬃciency of2 Journal of Biomedicine and Biotechnology
transduction [10]. CPPs can enter cells with a half-time of
1.8 minutes, corresponding to a ﬁrst-order rate constant
k of 0.007sec−1 [11]. Among the basic CPPs, the cellular
uptake of polyarginine tends to be more eﬃcient than that
of polylysine, polyhistidine, or polyornithine [12]. The high-
est translocation eﬃciencies were achieved by using octa-
arginineornona-argininepeptides[12].Thesyntheticnona-
arginine (SR9) peptide has been shown to eﬀectively deliver
not only covalently fused proteins but also noncovalently
bound protein into diﬀerent types of animal and plant cells
[9, 13].
The mechanism of cellular entry of CPPs has been the
focus of numerous studies. Early reports suggested that
CPPs delivery of molecules into cells was independent of
endocytosis, energy, receptors, or active transporters [14–
16] .H o w e v e r ,i tw a sl a t e rf o u n dt h a tﬁ x i n gc e l l sm a yh a v e
artiﬁcially transduced molecules across plasma membranes
[17]. More recent studies using live cell imaging suggested
the involvement of macropinocytosis [18, 19].
The goals of this study were to determine (1) whether
SR9 can noncovalently facilitate QD uptake and (2) the
internalization mechanisms for uptake of QD/SR9 complex.
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determine the eﬃciency of QD/SR9 uptake. Inhibitors and
siRNA were used to identify molecules and processes that
contribute to the uptake.
2.MaterialsandMethods
2.1. Quantum Dots. CdSe/ZnS quantum dots (Adirondack
Green, 520nm) were purchased from Evident Technologies
(Troy, NK, USA). These quantum dots have a polyethylene
glycol (PEG) lipid surface coated with carboxyl terminal
groups. The emission and excitation peak wavelengths
are 520nm and 505nm, respectively. The hydrodynamic
diameter is 25nm.
2.2.Nona-Arginines(SR9). Nona-argininesweresynthesized
bysolid-phasepeptidesynthesis(Sigma-Aldrich,SaintLouis,
MO, USA). The synthetic peptides were puriﬁed by high
performance liquid chromatography (HPLC) using a reverse
phase column. The purity of SR9 was ∼99%.
2.3. Chemicals. Fetal bovine serum, Ham’s F-12 medium
with L-glutamine, trypsin-EDTA (1x), penicillin-
streptomycin, sucrose, sodium azide, sodium ﬂuoride,
and chlorpromazine were purchased from Fisher Scientiﬁc
(Pittsburgh, PA, USA). Nystatin, ﬁlipin, 5-(N-ethyl-N-
isopropyl) amiloride (EIPA), cytochalasin D (Cyt D),
antimycin A, and monodansylcadaverine (MDC) were
purchased from Sigma-Aldrich.
2.4. Cell Culture. The human bronchoalveolar carcinoma-
derived cell line (A549) was purchased from ATCC (Manas-
sas, VA, USA). Cells were maintained in Ham’s F-12 medium
supplemented with 10% fetal bovine serum, 100units/mL
penicillin,and100μg/mLstreptomycinandgrownat37
◦Cin
a5 %C O 2 humidiﬁed environment. A549 cells were seeded
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Figure 1: Gel retardation analysis of the interaction between QDs
andSR9.QDswerepremixedwithSR9atdiﬀerentmolecularratios.
Lane 1: QDs without SR9. Lanes 2–5: QDs mixed with SR9 at ratios
of 10, 20, 30, and 60, respectively. The decrease in mobility reﬂected
the formation of QD/SR9 complexes.
into 35mm glass-bottom tissue culture plates (MatTek,
Ashland, MA, USA) at an initial conﬂuency of 20% and
allowed to attach for 48 hours.
2.5. Gel Retardation Assay. The QD and SR9 mixtures were
preparedatdiﬀerentmolecularratios(1:10,1:20,1:30,and
1:60) and then incubated for 20min at room temperature to
allow noncovalent complexes to form. These complexes were
analyzed by electrophoresis in a 0.6% agarose gel in 0.5%
TAE buﬀer at 130 voltages for 60min. The complexes were
visualized by UV light.
2.6. QD Uptake with SR9 at Diﬀerent Molecular Ratios. To
determine the optimal QD/SR9 ratio for eﬃcient delivery,
A549 cells were incubated with QD/SR9 at diﬀerent molec-
ular ratios (1:10 to 1:60). The cells were washed with ice-
cold phosphate buﬀered saline (PBS) six times to remove
unbound QD/SR9. Fluorescent images were then obtained
and quantiﬁed.
2.7.CytotoxicityMeasurement. To determine the cytotoxicity
of QD/SR9, A549 cells were treated with QD/SR9 (1:20)
at 12.5, 25, 50, 100, and 200nM QD concentrations for 24
hours. Untreated cells served as a control group. The MTS
assay (Cell Titer 96 Aqueous One Solution Assay, Promega,
Madison, WI, USA) was used to determine cytotoxicity.
Absorbance was measured at 490nm using a microplate
reader (FLOUstar, BMG Labtechnologies, Durham, NC,
USA).
2.8. Noncovalent Binding and Internalization of QDs and SR9.
QDs were premixed with SR9 peptides at the molecular
ratio of 1:20 at room temperature for 20min. immediatelyJournal of Biomedicine and Biotechnology 3
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Figure 2: QD uptake with SR9 at diﬀerent molecular ratios. QDs
were premixed with SR9 at molecular ratios from 1:10 to 1:60.
A549 cells were treated with QD/SR9. Values are mean ± SD
from three independent experiments. Fluorescence intensity is
normalized relative to the value at 1:10. ∗P<. 01 versus 1:10;
αP<. 01 versus 1:20.
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Figure 3: Time-dependent uptake of QD/SR9. QDs were premixed
with SR9 at a molecular ratio of 1:20. A549 cells were treated with
QD/SR9 at 150nM QD concentration for 5min, 20min, 40min, 1
hour, and 3 hours. Values are mean ± SD from three independent
experiments. Fluorescence intensity is normalized relative to the
value at 5min. ∗P<. 01 versus 5min; αP<. 01 versus 20min;
βP<. 01 versus 40min.
upon removal of medium, the cells were treated with the
QD/SR9 mixture at a ﬁnal QD concentration of 150nM for a
designated period of time. After treatment, cells were washed
six times with ice-cold PBS. Phenol red-free medium (2mL)
(Invitrogen, Carlsbad, CA, USA) was added for ﬂuorescent
image studies.
2.9. Uptake Studies
Energy Inhibition. To determine whether uptake of QD/SR9
is energy dependent, cells were incubated with QD/SR9
under varying metabolic conditions. In temperature studies,
cells were treated at either 37
◦Co r4 ◦C. In the low
temperature group, the cells were preincubated at 4◦Cf o r
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Figure 4: Cell viability of QD/SR9-treated cells. A549 cells were
treated with QD/SR9 (1:20) for 24 hours. The concentrations of
QDs used were 12.5, 25, 50, 100, and 200nM. Values are mean±SD
from three independent experiments.
30min and then treated with QD/SR9 at 4◦C for another 1-
hour. Cells maintained at 37
◦C comprised the control group.
In metabolic inhibition experiments, cells were incubated in
the absence or presence of a mixture of metabolic inhibitors
(0.15% sodium azide, 15mM sodium ﬂuoride, and 2μg/mL
antimycin A). Cells were pretreated with a mixture of
metabolic inhibitors for 1 hour followed by addition of
QD/SR9 to the cells and then incubated for another 1 hour.
Clathrin-DependantPathwayInhibition. Todisruptclathrin-
dependent endocytosis, hypertonic challenge, chlorpro-
mazine, and MDC were used. Cells were pretreated with
0.45M sucrose, 10μM chlorpromazine, or 25μg/mL MDC
for 30min. QD/SR9 was then added to the cells followed by
1 hour incubation.
Caveolin-DependantPathwayInhibition. Toinhibitcaveolin-
dependent endocytosis, ﬁlipin and nystatin were used to
deplete cholesterol. Cells were preincubated with 3μg/ml
ﬁlipin and 20μg/ml nystatin for 30min before treatment
with QD/SR9 for another 1 hour.
MacropinocytosisPathwayInhibition. EIPA(30μM)orCytD
(1μg/mL) was used to block macropinocytosis. Cells were
pretreated with the inhibitor for 30min before treatment
with QD/SR9 for another 1 hour.
2.10. Small Interfering RNA (siRNA) Transfection. Due to
potential nonspeciﬁc eﬀects and toxicity of pharmacolog-
ical inhibitors, clathrin heavy chain and caveolin-1 siRNA
(Sigma-Aldrich) were used to depress expression of critical
components of the clathrin and caveolarpathways.The sense
and antisense sequences of these siRNA were as follows.
Clathrin HC:
5 -CCCUAAACACCUCAACGAU-3  (sense)
5 -AUCGUUGAGGUGUUUAGGG-3  (antisense).4 Journal of Biomedicine and Biotechnology
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Figure 5: SR9 facilitates QD uptake. (a) The relative QD ﬂuorescence intensity in cells exposed to QD or QD/SR9. A549 cells were treated
with 150nM QDs and 150nM QD/SR9 (1:20) for 5min, 20min, 40min, and 60min. Fluorescence intensity is normalized relative to QDs
alone at 5min. (b) and (c) QD ﬂuorescence in cells with and without SR9 after a 5-minute exposure. (d) and (e) QD ﬂuorescence in cells
with and without SR9 after a 1-hour exposure. Images are from a single plane of Z series. Values are mean ± SD from three independent
experiments. Signiﬁcance is indicated by ∗P<. 01 versus QDs-alone group.
Caveolin-1:
5 -CAUUAUGACCGGGCUCAUA-3  (sense)
5 -UAUGAGCCCGGUCAUAAUG-3  (antisense).
Transfection of siRNA into the A549 cells was performed
at a ∼30% cell conﬂuence. siRNA was complexed with
Lipofectamine 2000 reagent according to the manufacturer’s
instructions (Invitrogen). Western blot and QD/SR9 uptake
studies were conducted 3 days after transfection.Journal of Biomedicine and Biotechnology 5
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Figure 6: Energy inhibition reduced internalization of QD/SR9 (150nM; 1:20; 1 hour). (a) Control cells. (b) Cells pretreated at 4◦Cf o r
30min then incubated with QD/SR9 for an additional 1 hour. (c) Cells pretreated with a metabolic inhibitor mixture for 1 hour then
incubated with QD/SR9 for an additional 1 hour. Images are from a single plane of Z series. (d) Fluorescence intensity. Values are mean±SD
from three independent experiments (∗P s <. 01 versus control).
2.11. Western Blot Analysis. A549 cells were lysed in a buﬀer
comprised of 150mM sodium chloride, 1.0% Triton X-100,
and 50mM Tris, pH 8.0, containing 1% protease inhibitor
cocktail (Sigma-Aldrich). The protein concentration was
quantiﬁed by the Bradford procedure (BioRad, Hercules,
CA, USA). Tenμg total cell protein was electrophoresed on
8% (clathrin-heavy chain) or 12% (caveolin-1) SDS-PAGE,
followed by electrotransfer to a nitrocellulose membrane.
Clathrin-heavy chain was detected using a mouse mono-
clonal antibody at a dilution of 1:200 and goat antimouse
IgG-HRP secondary antibody (Santa Cruz, CA, USA).
Caveolin-1 protein was detected using a rabbit monoclonal
antibody at a dilution of 1:1000 and goat antirabbit IgG-
HRP secondary antibody (Cell Signaling, Danvers, MA,
USA). The blots were probed with the ECL Western blot
detection system according to the manufacturer’s instruc-
tions (Thermo Fisher Scientiﬁc, Rockford, IL, USA). The
ImageJ software (NIH) was used for quantitative analysis of
the Western blot.
2.12. Epiﬂuorescent Microscopy. After treatment with
QD/SR9, cells were viewed with an Olympus IX51 inverted
microscope at 600X total magniﬁcation using a UPLFLN
60X NA 1.25 objective (Olympus, Center Valley, PA, USA).
QD ﬁlter set (EX 435/40, EM 519-700) was used for QDs
(Semrock, Rochester, NY, USA). Images were captured with
a Hamamatsu ORCA285 CCD camera. Z series images of
the entire cell volume were taken at 0.3μm internals . Images
were analyzed using SlideBook software (Intelligent Imaging
Innovations, Denver, CO, USA).
2.13. Statistical Analyses. Data were expressed as the
mean ± standard deviation from three independent exper-
iments. Fluorescent intensity was quantiﬁed using SlideBook
software. The mean ﬂuorescence intensity (after background
subtraction) of a single plane in Z series was recorded. One-
tailed unpaired Student’s t-test was used for signiﬁcance
testing, using P = .05.
3. Results
3.1. Formation of QD/SR9 Noncovalent Binding. To test
whether SR9 peptide stably associated with QDs, QDs
were mixed with SR9 at various molecular ratios (1:10,
1:20, 1:30, and 1:60). These mixtures were separated by
electrophoresisina0.6%agarosegel(Figure 1).QDmobility
decreased as the amount of SR9 increased. This indicated the
formation of noncovalent QD/SR9 complexes.
3.2. Molecular Ratio of QD and SR9 Aﬀects QD Uptake. To
determine the optimal ratio for cellular uptake, A549 cells
were incubated with QDs (150nM) preincubated with SR96 Journal of Biomedicine and Biotechnology
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Figure 7: Eﬀect of clathrin inhibitors on QD/SR9 internalization (150nM; 1:20; 1 hour). (a) Control cells. (b) Cells pretreated with
chlorpromazine for 30min then incubated with QD/SR9 for an additional 1 hour. (c) Cells pretreated with MDC for 30min then incubated
with QD/SR9 for an additional 1 hour. Images are from a single plane of Z series. (d) Fluorescence intensity. Values are mean ± SD from
three independent experiments (∗P s <. 01 versus control).
at diﬀerent molecular ratios. QD uptake was increased as
the ratio of SR9 increased from 1:10 to 1:30 (P s<. 01)
(Figure 2). However, there was no increase in the amount
of internalization at ratios above 1:30. Although the uptake
reaches the highest level at 1:30, good imaging quality can
be obtained at 1:20. Further, in the future we intend to use
this system to carry cargoes which requires binding sites on
quantum dots. Accordingly, we chose to use 1:20 as the ratio
between QDs and SR9.
3.3. Time-Dependent Uptake. To determine the optimal
dosing time, A549 cells were incubated with QD/SR9 (1:20)
for 5min, 20min, 40min, 1 hour, and 3 hours. Compared to
the 5-minute group, the uptake of QD/SR9 was increased by
1.67 ±0.37-fold in 20min (P s<. 01) (Figure 3). The uptake
was near maximal at 1-hour. Accordingly, the 1 hour uptake
time point was used in subsequent experiments.
3.4. Cytotoxicity of QD/SR9. To assess the cytotoxicity of
QD/SR9 complex, A549 cells were exposed to QD/SR9
(1:20) complex at various QD concentrations for 24 hours.
No cytotoxicity of QD/SR9 was observed at concentrations
up to 200nM (Figure 4).
3.5. Cellular Uptake of QDs Facilitated by SR9 Peptide. To
determine the ability of SR9 peptide to facilitate QD delivery,
A549 cells were treated with 150nM QDs alone or 150nM
QDs premixed with SR9 at a ratio of 1:20. After incubation
of 5min, 20min, 40min, and 60min, QDs-treated cells were
observedunderanepiﬂuorescencemicroscope.Imagestaken
using the same exposure time show that enhanced uptake of
the QD/SR9 complex was observed compared to QD alone
(Figures 5(b)–5(e)). Quantitation of ﬂuorescence intensities
shows that compared with QD alone in ﬁve minutes, the
uptake of QD/SR9 increased by 3–8-folds (Figure 5(a)).
3.6. Mechanism of QD/SR9 Internalization. Endocytosis,
an essential cellular process for internalizing extracellular
materials, utilizes several distinct pathways. To determine
the mechanism of SR9-mediated QD delivery, a series of
inhibition studies were carried out.
3.6.1. Energy-Dependent Studies. To determine whether
uptake of QD/SR9 is mediated by energy-dependent endo-
cytosis, we used low temperature or a mixture of metabolic
inhibitors to deplete intracellular energy (Figure 6). In the
lowtemperaturestudy,thecellswereincubatedwithQD/SR9
at 37
◦Co r4 ◦C. As shown in Figures 6(a) and 6(b), QD/SR9
internalization was signiﬁcantly impeded at 4◦C; the ﬂuores-
cenceintensityat4◦Cwas73±11.5%lowerthanthatat37
◦C
(P<. 01) (Figure 6(d)). In the metabolic inhibition study,
A549 cells were incubated with QD/SR9 in the presence or
absence of a mixture of metabolic inhibitors (0.15% sodium
azide, 15mM sodium ﬂuoride, and 2μg/mL antimycin A).Journal of Biomedicine and Biotechnology 7
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Figure 8: Lipid raft/caveolin inhibition decreased QD/SR9 internalization (150nM; 1:20; 1 hour). (a) Control cells. (b) Cells pretreated
with nystatin for 30min then incubated with QD/SR9 for an additional 1 hour. (c) Cells pretreated with ﬁlipin for 30min then incubated
with QD/SR9 for an additional 1 hour. Images are from a single plane of Z series. (d) Fluorescence intensity. Values are mean ± SD from
three independent experiments (∗P s <. 01 versus control).
These metabolic inhibitors strongly inhibited the uptake of
QD/SR9 (Figures 6(a) and 6(c)). The ﬂuorescent intensity
in the presence of metabolic inhibitors was 61 ± 5.7% lower
than that in the control group (P<. 01) (Figure 6(d)).
3.6.2. Clathrin-Dependent Pathway. To perturb the clathin-
dependent uptake pathway, three methods were used: mon-
odansylcadaverine (MDC), hypertonic sucrose, and chlor-
promazine. The inhibitory activity of MDC is attributed to
the stabilization of nascent clathrin-coated vesicles, which
limits new clathrin-coated vesicle production [20]. The
underlying mechanism of hypertonic sucrose involves the
dispersion of clathrin lattices on the plasma membrane
[21]. Chlorpromazine is a cationic amphipathic drug that
relocates clathrin and adaptor protein complex-2 (AP-2)
from the plasma membrane to the endosomal membrane
[22]. MDC reduced the uptake of QD/SR9 by 44 ± 13.0%
(P<. 01)whilehypertonicmediumdecreaseduptakeby59%
(P<. 01; data not shown). In contrast, chlorpromazine only
slightly reduced uptake by 14 ±12.1% (P>. 05) (Figure 7).
3.6.3. Lipid Raft/Caveolin-Dependent Pathway. Nystatin and
ﬁlipin, lipid raft inhibitors, are used to block the caveolin-
dependent endocytic pathway [23, 24]. Treatment of cells
with these two inhibitors reduced the QD/SR9 internaliza-
tion by 32 ± 8.6% and 35 ± 15.5%, respectively, (P s <. 01)
(Figure 8), indicating that a lipid raft-dependent process is
involved in QD/SR9 internalization.
3.6.4. Macropinocytosis Pathway. 5-(N-ethyl-N-isopropyl)
amiloride (EIPA) is an inhibitor of the Na+/H+ exchange
that is required for macropinocytosis [25]. Cytochalasin D
(Cyt D) is an F-actin depolymerizing drug that caps the
barbed, faster-growing ends of actin ﬁlaments [26]. EIPA
reduced the uptake of QD/SR9 by 47 ± 14.3% (P<. 01)
(Figure 9). To conﬁrm the eﬀective concentration of Cyt
D, we used Alexa 568—phalloidin to stain actin of Cyt
D-treated and control cells. Actin was depolymerized in
A549cells by 1μg/mL Cyt D (data not shown). Cyt D
signiﬁcantly reduced the uptake of QDs (P<. 01) (Figure 9).
Condensed green ﬂuorescent agglomerates were observed
around the cellular surface following treatment with Cyt D
(Figure 9(c)).
3.7. siRNA Knockdown. To complement the use of phar-
macological inhibitors, we used the RNAi techniques to
eliminate expression of speciﬁc components of the various
uptake mechanisms. Clathrin HC and caveolin-1 siRNA
were used to knock down clathrin-dependent and caveolin-
depedent pathways, respectively. The Western blot experi-
ments demonstrated the results of the knockdown treatment
(Figure 10). The protein expression of clathrin and caveolin-
1w a sr e d u c e db y9 3± 7.2% and 73 ± 5.7%, respectively,
(P s<. 01). Following clathrin HC or caveolin-1 protein
knockdown, the uptake of QD/SR9 was not signiﬁcantly
aﬀected (Figure 11).8 Journal of Biomedicine and Biotechnology
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Figure 9: Macropinocytosis inhibition perturbed QD/SR9 internalization (150nM; 1:20; 1 hour). (a) Control cells. (b) Cells pretreated
with EIPA for 30min then incubated with QD/SR9 for an additional 1 hour. (c) Cells pretreated with Cyt D for 30min then incubated with
QD/SR9 for an additional 1 hour. Images are from a single plane of Z series. (d) Fluorescence intensity. Values are mean ± SD from three
independent experiments (∗P s <. 01 versus control).
4. Discussion
Quantum dots are an emerging class of ﬂuorescent probes
for cellular imaging. In comparison with organic dyes and
ﬂuorescent proteins, QDs have unique properties, including
high quantum yield and photostability, which make them
better suited for delivering and monitoring biomolecules.
The eﬃciency of internalizing QDs can be improved by
incorporating cell-penetrating peptides [5]. Accordingly, our
goals were to test whether nona-arginine (SR9) facilitates
QD uptake and to determine the mechanism of this uptake.
Data from this study demonstrate that QDs are internalized
into A549 cells within 5min with the aid of SR9; without
SR9, QD uptake is minimal (Figure 5). The enhancement
of internalization by basic protein transducers is thought to
reﬂect an electrostatic interaction between cationic nona-
arginine and the negatively charged polar heads of the
phospholipids of the plasma membrane [18]. Our study
demonstrates that SR9 can signiﬁcantly increase QD uptake.
QD/SR9 internalization was dramatically blocked by
either low temperature or a mixture of metabolic inhibitors.
This indicates that the uptake of QD/SR9 is highly energy-
dependent and supports the notion that endocytosis is
the major uptake process. Since endocytosis encompasses
numerous pathways, our subsequent studies were designed
to further elucidate the speciﬁc mechanism of uptake.
Clathrin-dependent endocytosis is a well-characterized
endocytic pathway. To determine the role of clathrin-
mediated uptake of QD/SR9, we used three diﬀerent
inhibitors. Treating cells with hypertonic sucrose signif-
icantly reduced QD/SR9 uptake. Although this kind of
inhibition is considered evidence of clathrin-dependent
endocytosis, recent studies have suggested that it also
interferes with other internalization pathways, including
caveolin-dependent endocytosis and macropinocytosis [27].
Accordingly, the eﬀects of two additional inhibitors, MDC
and chlorpromazine, were determined. MDC signiﬁcantly
impeded QD/SR9 internalization. Though MDC is consid-
ered as a clathrin pathway inhibitor, it is also a macropinocy-
tosisinhibitorviasuppressionofthetransglutaminasefamily
that activates Rho GTPases, the key regulators of actin
assembly and dynamics [27]. Thus, MDC might block actin-
dependent pathways such as macropinocytosis. Chlorpro-
mazine had only a small eﬀect on uptake. Due to the varying
results and possible oﬀ-target eﬀects of the inhibitor studies,
we used siRNA to knock down clathrin heavy chain. The
Western blot analysis indicated that near complete clathrin
protein (93 ± 5.7%) expression was suppressed. The almost
complete loss of clathrin did not aﬀect the QD ﬂuorescence
intensity inside cells relative to control levels. Together,
our data suggest that clathrin-mediated endocytosis is not
required for QD/SR9 internalization. However, becauseJournal of Biomedicine and Biotechnology 9
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Figure 10: Western blot analysis of clathrin HC and caveolin-1 protein after siRNA treatment. A549 cells were treated with siRNA of clathrin
HC or caveolin-1 protein for 3 days, and then cells were lysed for Western blot analysis. (a) Clathrin HC protein expression in A549 cells.
(b) Caveolin-1 protein expression in A549 cells. β-actin was used as the internal control. (c) and (d) Quantiﬁcation analysis of the Western
blots. Intensity is normalized to the siRNA untreated group. Values are mean ± SD from three independent experiments (∗P s <. 01 versus
control).
clathrin protein was not completely eliminated, we cannot
rule out that clathrin is involved in QD/SR9 uptake.
Nystatin and ﬁlipin are polyene antibiotics that accumu-
late cholesterol and thereby sequester lipid from cell mem-
branes. Nystatin and ﬁlipin are highly selective inhibitors
of the lipid raft-dependent pathway because of this lipid
sequestering [23, 24]. Both inhibitors hindered the uptake
of QD/SR9, suggesting that the internalization was lipid raft
dependent. Cholesterol depletion could result in blockage of
several lipid raft-dependent endocytic pathways, including
caveolae-dependent and macropinocytic pathways [24]. For
further clariﬁcation, caveolin-1 siRNA was used to knock-
down caveolin-1 expression. The Western blot analysis and
live cell imaging indicated that internalization of QD/SR9
was not reduced while caveolin-1 protein was knocked
down by 73 ± 7.2%. These ﬁndings suggest that QD/SR9
internalization is a lipid raft-dependent process that is
not mainly caveolin-mediated. Because caveolin-1 protein
was not completely knock down, we cannot rule out that
caveolin-1 was involved in QD/SR9 uptake.10 Journal of Biomedicine and Biotechnology
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Figure 11: QD/SR9 uptake after knockdown of clathrin HC and caveolin-1 protein (150nM; 1:20; 1 hour). A549 cells were treated with
siRNA of clathrin HC or caveolin-1 protein for 3 days, and then cells were used for uptake studies. (a) Control cells. (b) Cells pretreated with
clathrin HC siRNA. (c) Cells pretreated with caveolin-1 siRNA. Images are from a single plane of Z series. (d) Fluorescence intensity. Values
are mean ±SD from three independent experiments.
Macropinocytosis is a rapid, lipid raft-dependent, and
receptor-independent form of endocytosis. Macropinocyto-
sis includes three essential steps: actin cytoskeleton-driven
ruﬄe formation, closure of the ruﬄe into a vesicle, and
dissociation of actin ﬁlaments from the vesicle [28]. The
ﬂuorescent intensities in cells treated with two macropinocy-
tosis inhibitors, EIPA and Cyt D, were signiﬁcantly reduced
compared to the control cells. It is worth noting that in
Cyt D-treated cells, QD/SR9 was densely localized around
cellular surfaces, not in cytosol, leading to overestimate of
QD/SR9 internalization. This is similar with the observation
of Nakase et al. that cellular R8 peptide was predominantly
localized in cellular boundaries with very little punctuate
staininginCytD-treatedcells[29].Ruanetal.madeasimilar
observationwithCytD-treatedcells[6].Itisunclearhowthe
dense aggregates aﬀect quantitation. In summary the uptake
of QD/SR9 is lipid raft-dependent macropinocytosis.
Collectively, our data show that SR9 facilitates a rapid
energy-dependent cellular entry of QDs. The internalization
involves lipid raft and depends on macropinocytosis. Other
pathways such as RhoA-dependent and CDC42-dependent
endocytic pathways may also deserve attention [30, 31].
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